Propanidid
An intravenous anesthetic agent
| Propanidid | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Propanidid is a short-acting intravenous anesthetic agent that was used primarily for the induction of general anesthesia. It is a member of the phenylacetate class of anesthetics and was introduced in the 1960s. Due to its rapid onset and short duration of action, it was particularly useful in situations requiring quick recovery times.
Pharmacology[edit]
Propanidid acts on the central nervous system to produce a state of unconsciousness. It works by enhancing the activity of the gamma-aminobutyric acid (GABA) neurotransmitter, which is the primary inhibitory neurotransmitter in the brain. This action results in the depression of the central nervous system, leading to anesthesia.
Chemical Structure[edit]
Propanidid is chemically classified as an ester of phenylacetic acid. Its structure includes a phenyl ring, which is responsible for its lipophilic properties, allowing it to rapidly cross the blood-brain barrier.
Clinical Use[edit]
Propanidid was primarily used for the induction of anesthesia in surgical procedures. Its rapid onset made it suitable for use in day surgery and other procedures where quick recovery was desired. However, due to the development of newer anesthetics with improved safety profiles, its use has declined.
Side Effects[edit]
The use of Propanidid was associated with several side effects, including hypotension, respiratory depression, and allergic reactions. These adverse effects limited its use and led to the development of alternative agents.
History[edit]
Propanidid was developed in the 1960s and was one of the first intravenous anesthetics to be used clinically. It was marketed under various brand names and was widely used until the 1980s, when it was largely replaced by newer agents such as propofol.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
